Compare TFIN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | PGEN |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | TFIN | PGEN |
|---|---|---|
| Price | $64.31 | $4.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $62.00 | $7.67 |
| AVG Volume (30 Days) | 231.1K | ★ 3.6M |
| Earning Date | 01-21-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $412,291,000.00 | $6,309,000.00 |
| Revenue This Year | $10.27 | $342.78 |
| Revenue Next Year | $9.56 | $478.46 |
| P/E Ratio | $222.61 | ★ N/A |
| Revenue Growth | 3.78 | ★ 59.20 |
| 52 Week Low | $42.90 | $0.65 |
| 52 Week High | $100.87 | $5.23 |
| Indicator | TFIN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 55.69 |
| Support Level | $60.87 | $3.64 |
| Resistance Level | $63.55 | $3.75 |
| Average True Range (ATR) | 2.64 | 0.24 |
| MACD | 0.55 | 0.03 |
| Stochastic Oscillator | 95.37 | 87.97 |
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.